Abstract

155P A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract CT129: A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors
Chia-Jui Yen ... Daneng Li
Cancer Research | VOL. 82
Chia-Jui Yen, et. al.Chia-Jui Yen ... Daneng Li
15 Jun 2022
Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors
Jeffrey Clarke ... Giuseppe Curigliano
Molecular Cancer Therapeutics | VOL. 18
Jeffrey Clarke, et. al.Jeffrey Clarke ... Giuseppe Curigliano
01 Dec 2019
Abstract OT2-16-01: ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)
Amelia B Zelnak ... Kathy D Miller
Cancer Research | VOL. 83
Amelia B Zelnak, et. al.Amelia B Zelnak ... Kathy D Miller
01 Mar 2023
Abstract CT126: A phase I first time in human study to evaluate the safety, pharmacokinetics, and immunogenicity of MEDI5083 alone and in combination with durvalumab in selected advanced solid tumors
Victoria L Chiou ... Martin Gutierrez
Cancer Research | VOL. 78
Victoria L Chiou, et. al.Victoria L Chiou ... Martin Gutierrez
01 Jul 2018
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy – a retrospective and biomarker study
Fernanda Costa Svedman ... Suzanne Egyhazi Brage
Immuno-Oncology and Technology | VOL. -
Fernanda Costa Svedman, et. al.Fernanda Costa Svedman ... Suzanne Egyhazi Brage
01 May 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial
Caroline Dive ... Kirellos S Abbas
Immuno-Oncology and Technology | VOL. 22
Caroline Dive, et. al.Caroline Dive ... Kirellos S Abbas
18 Mar 2024
Table of Contents
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
View more papers